Fig. 4

Functional activity of HLA-A2 CAR-Tregs through the target antigen HLA-A*02. a Percentage of CD69 + cells among CAR-Tregs under conditions of no activation (negative control), polyclonal activation through the T cell receptor (TCR) with anti-CD3/anti-CD28 (aCD3/aCD8) coated beads (positive control), specific activation via the CAR using HLA-A*02^pos PBMC or control (incubation with HLA-A*02^neg PBMC). Delta PBMC is the difference in percentage of CD69⁺ cells under activation conditions of HLA-A*02^pos PBMCs versus HLA-A*02^neg PBMCs. b Ratio of ATP production measured by bioluminescence assay for HLA-A2 CAR Tregs activated through their TCR (positive control) versus no activation (negative control) or HLA-A2 CAR Tregs activated with the target antigen HLA-A*02 using HLA-A2 Dextramer versus Dextramer blank (control). Boxplots show data for batches of TX200-TR101 manufactured from patients with ESRD (n = 4) and healthy donors (n = 6)¹. The box represents the interquartile range; the median value divides the box in two parts; whiskers represent minimum and maximum values; X represents the mean value. Individual data points (other than minimum and maximum values) are shown as open circles. No statistically significant differences in the means between the two populations (ESRD patients vs healthy donors) were observed. ¹There was insufficient final product available from 4 of the healthy donors for all of the tests; consequently, the activation assay and the proliferation assay were only conducted on 6 out of the 10 batches manufactured from healthy donor material